A must read article on Vioxx

Todays online version of The Wall Street Journal, or the weekend news stand edition, both have the most comprehensive discussion and review of the NEJM article, it's impact on litigation, the swelling anger in the medical community and the outlook for Merck.

I know it's subscription based but you really need to getting their updates if you want to get some of the top reporting on most of the pharmaceutical and product liability litigation currently happening in the US.

You don't have to read too far between the lines to realize that things are unwinding at a rapid rate for Merck, with the call for a mistrial just the first, most public, step. When the WSJ starts to intimate that your in trouble, well, you are probably in big trouble.